Personalizing Adjuvant Endocrine Therapy for Early-Stage Hormone Receptor–Positive Breast Cancer
出版年份 2022 全文链接
标题
Personalizing Adjuvant Endocrine Therapy for Early-Stage Hormone Receptor–Positive Breast Cancer
作者
关键词
-
出版物
American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting
Volume -, Issue 42, Pages 1-13
出版商
American Society of Clinical Oncology (ASCO)
发表日期
2022-05-28
DOI
10.1200/edbk_350358
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update
- (2022) Andrea Eisen et al. JOURNAL OF CLINICAL ONCOLOGY
- Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials
- (2022) Rosie Bradley et al. LANCET ONCOLOGY
- Sentinel Node Biopsy Should Not be Routine in Older Patients with ER-Positive HER2-Negative Breast Cancer Who Are Willing and Able to Take Hormone Therapy
- (2021) Elaine McKevitt et al. ANNALS OF SURGICAL ONCOLOGY
- Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer—The Penelope-B Trial
- (2021) Sibylle Loibl et al. JOURNAL OF CLINICAL ONCOLOGY
- Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: a multicentre, open-label, randomised, phase 3 trial
- (2021) Lucia Del Mastro et al. LANCET ONCOLOGY
- Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast Cancer
- (2021) Michael Gnant et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prognosis of Patients With Early Breast Cancer Receiving 5 Years vs 2 Years of Adjuvant Bisphosphonate Treatment
- (2021) Thomas W. P. Friedl et al. JAMA Oncology
- Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study
- (2021) N. Harbeck et al. ANNALS OF ONCOLOGY
- Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03)
- (2021) Michael Gnant et al. JOURNAL OF CLINICAL ONCOLOGY
- 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer
- (2021) Kevin Kalinsky et al. NEW ENGLAND JOURNAL OF MEDICINE
- Outcome without any adjuvant systemic treatment in stage I ER+/HER2− breast cancer patients included in the MINDACT trial
- (2021) J.M.N. Lopes Cardozo et al. ANNALS OF ONCOLOGY
- Trends in Surgical Axillary Management in Early Stage Breast Cancer in Elderly Women: Continued Over-Treatment
- (2020) Raphael J. Louie et al. ANNALS OF SURGICAL ONCOLOGY
- Oral GnRH antagonist Ovarian Suppression after Escape from GnRH agonist in Breast Cancer Patients
- (2020) Kathryn Coyne et al. Clinical Breast Cancer
- Serum Detection of Nonadherence to Adjuvant Tamoxifen and Breast Cancer Recurrence Risk
- (2020) Barbara Pistilli et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial
- (2019) Michael Gnant et al. LANCET ONCOLOGY
- Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Local and Contralateral Recurrence in Breast Intraepithelial Neoplasia
- (2019) Andrea DeCensi et al. JOURNAL OF CLINICAL ONCOLOGY
- Adding Ovarian Suppression to Tamoxifen for Premenopausal Breast Cancer: A Randomized Phase III Trial
- (2019) Hyun-Ah Kim et al. JOURNAL OF CLINICAL ONCOLOGY
- Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the Adjuvant Tamoxifen—To Offer More? (aTTom) trial
- (2019) J M S Bartlett et al. ANNALS OF ONCOLOGY
- Twist1-induced epithelial dissemination requires Prkd1 signaling
- (2019) Dan Georgess et al. CANCER RESEARCH
- Phase III randomized trial of bisphosphonates as adjuvant therapy in breast cancer: S0307
- (2019) Julie R Gralow et al. JNCI-Journal of the National Cancer Institute
- Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial
- (2019) Robert Coleman et al. LANCET ONCOLOGY
- PAM50 Risk of Recurrence Score Predicts 10-Year Distant Recurrence in a Comprehensive Danish Cohort of Postmenopausal Women Allocated to 5 Years of Endocrine Therapy for Hormone Receptor–Positive Early Breast Cancer
- (2018) Anne-Vibeke Lænkholm et al. JOURNAL OF CLINICAL ONCOLOGY
- Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer
- (2018) Prudence A. Francis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer
- (2018) Joseph A. Sparano et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update
- (2018) Harold J. Burstein et al. JOURNAL OF CLINICAL ONCOLOGY
- Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2018) Eleftherios P Mamounas et al. LANCET ONCOLOGY
- Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: A Cancer Care Ontario and American Society of Clinical Oncology Clinical Practice Guideline
- (2017) Sukhbinder Dhesy-Thind et al. JOURNAL OF CLINICAL ONCOLOGY
- MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
- (2017) Matthew P. Goetz et al. JOURNAL OF CLINICAL ONCOLOGY
- Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials
- (2017) Poornima Saha et al. JOURNAL OF CLINICAL ONCOLOGY
- Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05)
- (2017) Erik J Blok et al. JNCI-Journal of the National Cancer Institute
- Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial
- (2017) Vivianne C G Tjan-Heijnen et al. LANCET ONCOLOGY
- 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years
- (2017) Hongchao Pan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05)
- (2017) Erik J Blok et al. JNCI-Journal of the National Cancer Institute
- Two Years of Adjuvant Tamoxifen Provides a Survival Benefit Compared With No Systemic Treatment in Premenopausal Patients With Primary Breast Cancer: Long-Term Follow-Up (> 25 years) of the Phase III SBII:2pre Trial
- (2016) Maria Ekholm et al. JOURNAL OF CLINICAL ONCOLOGY
- Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
- (2016) Massimo Cristofanilli et al. LANCET ONCOLOGY
- 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
- (2016) Fatima Cardoso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years
- (2016) Paul E. Goss et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
- (2016) Gabriel N. Hortobagyi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and intrinsic subtype
- (2015) M. Gnant et al. ANNALS OF ONCOLOGY
- Development and verification of the PAM50-based Prosigna breast cancer gene signature assay
- (2015) Brett Wallden et al. BMC Medical Genomics
- St. Gallen/Vienna 2015: A Brief Summary of the Consensus Discussion
- (2015) Michael Gnant et al. Breast Care
- Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials
- (2015) LANCET
- Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials
- (2015) LANCET
- Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial
- (2015) Ian H Kunkler et al. LANCET ONCOLOGY
- Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials
- (2015) Jürg Bernhard et al. LANCET ONCOLOGY
- Prospective Validation of a 21-Gene Expression Assay in Breast Cancer
- (2015) Joseph A. Sparano et al. NEW ENGLAND JOURNAL OF MEDICINE
- Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12
- (2014) M. Gnant et al. ANNALS OF ONCOLOGY
- Phase III Comparison of Tamoxifen Versus Tamoxifen Plus Ovarian Function Suppression in Premenopausal Women With Node-Negative, Hormone Receptor–Positive Breast Cancer (E-3193, INT-0142): A Trial of the Eastern Cooperative Oncology Group
- (2014) Amye J. Tevaarwerk et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update
- (2014) Harold J. Burstein et al. JOURNAL OF CLINICAL ONCOLOGY
- Cognitive Function After the Initiation of Adjuvant Endocrine Therapy in Early-Stage Breast Cancer: An Observational Cohort Study
- (2014) Patricia A. Ganz et al. JOURNAL OF CLINICAL ONCOLOGY
- The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2− breast cancer patients
- (2013) P Dubsky et al. BRITISH JOURNAL OF CANCER
- Comparison of PAM50 Risk of Recurrence Score With Oncotype DX and IHC4 for Predicting Risk of Distant Recurrence After Endocrine Therapy
- (2013) Mitch Dowsett et al. JOURNAL OF CLINICAL ONCOLOGY
- Prediction of Late Disease Recurrence and Extended Adjuvant Letrozole Benefit by the HOXB13/IL17BR Biomarker
- (2013) Dennis C. Sgroi et al. JNCI-Journal of the National Cancer Institute
- Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results
- (2012) R. Coleman et al. ANNALS OF ONCOLOGY
- Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial
- (2012) Christina Davies et al. LANCET
- Association Between Prescription Co-Payment Amount and Compliance With Adjuvant Hormonal Therapy in Women With Early-Stage Breast Cancer
- (2011) Alfred I. Neugut et al. JOURNAL OF CLINICAL ONCOLOGY
- Toxicity of Adjuvant Endocrine Therapy in Postmenopausal Breast Cancer Patients: A Systematic Review and Meta-analysis
- (2011) Eitan Amir et al. JNCI-Journal of the National Cancer Institute
- Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up
- (2011) Meredith M Regan et al. LANCET ONCOLOGY
- Bone turnover across the menopause transition
- (2010) Kristy M. Nicks et al. Annals of the New York Academy of Sciences
- A Comparison of PAM50 Intrinsic Subtyping with Immunohistochemistry and Clinical Prognostic Factors in Tamoxifen-Treated Estrogen Receptor-Positive Breast Cancer
- (2010) T. O. Nielsen et al. CLINICAL CANCER RESEARCH
- Tolerance of adjuvant letrozole outside of clinical trials
- (2008) C. Fontaine et al. BREAST
- Benefit From Exemestane As Extended Adjuvant Therapy After 5 Years of Adjuvant Tamoxifen: Intention-to-Treat Analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 Trial
- (2008) Eleftherios P. Mamounas et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy
- (2008) Michael Gnant et al. LANCET ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started